Дата |
---|
07.05.2024 |
06.05.2024 |
03.05.2024 |
02.05.2024 |
01.05.2024 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
25.04.2024 |
24.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
1.55
|
1.72
|
1.77
|
1.54
|
1.77
|
1.60
|
|
|
6 287.16
|
49.00
|
1.44
|
1.78
|
1.75
|
1.70
|
1.88
|
1.70
|
|
|
6 118.41
|
23.00
|
1.71
|
2.08
|
1.85
|
1.71
|
1.85
|
1.73
|
|
|
1 292.49
|
25.00
|
1.66
|
2.00
|
1.90
|
1.7899
|
2.03
|
1.7899
|
|
|
10 091.47
|
27.00
|
1.80
|
1.95
|
1.78
|
1.78
|
1.9822
|
1.9822
|
|
|
3 664.46
|
29.00
|
1.21
|
2.38
|
1.73
|
1.72
|
1.87
|
1.84
|
|
|
3 050.59
|
33.00
|
1.66
|
1.85
|
1.59
|
1.59
|
1.78
|
1.7301
|
|
|
5 143.27
|
16.00
|
1.59
|
1.92
|
1.72
|
1.58
|
1.72
|
1.59
|
|
|
6 858.34
|
23.00
|
1.38
|
1.81
|
1.66
|
1.66
|
1.69
|
1.69
|
|
|
469.46
|
10.00
|
1.38
|
1.62
|
1.55
|
1.55
|
1.69
|
1.64
|
|
|
10 503.75
|
23.00
|
Biofrontera Inc. (Biofrontera) is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions. With a focus on the fields of photodynamic therapy (PDT) and topical antibiotics, Biofrontera currently commercializes the FDA-approved flagship drug Ameluz (aminolevulinic acid hydrochloride gel, 10%) in the United States. When used in combination with PDT and Biofrontera’s BF-RhodoLED lamp, Ameluz-PDT is indicated for the treatment of actinic keratoses (AK), one of the most common precancerous skin conditions. Biofrontera also commercializes the drug Xepi (ozenoxacin cream, 1%), FDA-approved for the treatment of impetigo.
In collaboration with dermatologists, Biofrontera is fully committed to advancing treatment options and patient care.
Показать все Скрыть